http://www.w3.org/ns/prov#value | - o discover or identify new protein biomarkers and use such information to develop ovarian cancer or OVA1 diagnostic products; (4) uncertainty as to whether Vermillion will be able to obtain any required regulatory approval of its ovarian cancer or OVA1 diagnostic products; (5) uncertainty of market acceptance of its ovarian cancer or OVA1 diagnostic products, including the risk that its products w
|